Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced management will present at three investor conferences in March 2026: Leerink Global Healthcare (Mar 10, 3:00 p.m. ET, Miami), Citizens Life Sciences (Mar 11, 2:50 p.m. ET, Miami), and RBC Capital Markets Global Ophthalmology (Mar 25, 11:45 a.m. ET, virtual).

Links to webcasts are available on the company's Investors > Events webpage.

Argus Mar 3 session

-1.85% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – IRD

On Mar 3, the day this news came out, IRD closed 1.85% below the previous close.

Data tracked by StockTitan Argus for the Mar 3 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the following investor conferences.

Leerink Global Healthcare Conference

• Date: Tuesday, March 10, 2026
• Time: 3:00 p.m. ET
• Location: Miami, FL
  
  

Citizens Life Sciences Conference

• Date: Wednesday, March 11, 2026
• Time: 2:50 p.m. ET
• Location: Miami, FL
  
  

RBC Capital Markets Global Ophthalmology Conference

• Date: Wednesday, March 25, 2026
• Time: 11:45 a.m. ET
• Location: Virtual
  
  

Links to the conference webcasts may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Opus Genetics (IRD) present at the Leerink Global Healthcare Conference?

Opus Genetics will present on Tuesday, March 10, 2026 at 3:00 p.m. ET. According to the company, the presentation takes place in Miami and may include corporate updates and program progress relevant to investors.

How can investors watch Opus Genetics (IRD) at the RBC Capital Markets Global Ophthalmology Conference?

The RBC Capital Markets presentation will be virtual on Wednesday, March 25, 2026 at 11:45 a.m. ET. According to the company, webcast links will be posted under Investors > Events on its website for live access.

What time is Opus Genetics (IRD) scheduled at the Citizens Life Sciences Conference on March 11, 2026?

Opus Genetics is scheduled for Wednesday, March 11, 2026 at 2:50 p.m. ET. According to the company, the session is in Miami and is intended to inform investors about clinical programs and corporate strategy.

Will Opus Genetics (IRD) provide webcasts for its March 2026 investor presentations?

Yes, webcast links will be available via the company's website under Investors > Events. According to the company, links to the conference webcasts may be accessed on that Events page for each presentation.

What topics is Opus Genetics (IRD) likely to cover at the March 2026 investor conferences?

Presentations typically cover clinical programs, pipeline updates, and corporate strategy. According to the company, management will present investor-focused updates related to its gene therapies for inherited retinal diseases.